



## Precision Medicine in Hepatobiliary Cancer: Preclinical and Clinical Evidence

Guest Editor:

**Prof. Dr. Diego F. Calvisi**

Institute of Pathology, University  
of Regensburg, 93053  
Regensburg, Germany


Deadline for manuscript  
submissions:  
**closed (5 April 2022)**

### Message from the Guest Editor

Primary liver cancer (PLC) is a frequent and deadly tumor worldwide. PLC consists mainly of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) in the adult, whereas hepatoblastoma (HB) is the prevalent hepatic malignancy in childhood.

In the last decade, as in many other tumor types, whole-genome sequencing studies together with a plethora of transcriptomic, proteomic, and metabolomic approaches have unraveled the molecular landscape of PLC. In addition, several in vitro and in vivo models have been generated to evaluate the possible vulnerability of tumors to innovative therapies. As a result, specific genetic and epigenetic events and peculiar metabolic features of the tumors have been identified. Effective and highly specific therapeutic approaches have been developed for some of them, and the concept of “precision medicine” (one patient = one treatment) has been established.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)